Concepedia

Gregory McAllister

GM

Statistics

Publications

24

Citations

4.3K

H-Index

20

Active since

2002

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Novartis (United States)

Pathways Behavioral Services

Novartis (China)

Gregory McAllister is an author at Novartis (Switzerland) specializing in life sciences, molecular biology, and molecular oncology.

Publications per year

2002–2021

24

Publications

24

p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

Robert J. Ihry, Kathleen A. Worringer, Max R. Salick et al. · Nature Medicine · 2018 · 1K citations

, , +12

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

E. Robert McDonald, Antoine de Weck, Michael R. Schlabach et al. · Cell · 2017 · 701 citations · Full text

, , +17

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

Gregory R. Hoffman, Rami Rahal, Frank P. Buxton et al. · Proceedings of the National Academy of Sciences · 2014 · 416 citations · Full text

, , +17

CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions

Diana M. Muñoz, Pamela J. Cassiani, Li Li et al. · Cancer Discovery · 2016 · 398 citations

, , +13

DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery

Chaoyang Ye, Daniel Ho, Marilisa Neri et al. · Nature Communications · 2018 · 238 citations · Full text

, , +10

1–5 of 24